My watch list  

38 Current news of Evonik


You can refine your search further. Select from the filter options on the left to narrow down your results.

Evonik increases prices of pharmaceutical amino acids


Effective immediately, Evonik Industries is increasing the prices of its pharmaceutical amino acids. The increase, of between 10 and 15 percent depending on the amino acid and its quality, applies globally to all new orders and new supply agreements. The price increase is a result of the ...


Evonik finalizes acquisition of Boehringer Ingelheim's RESOMER business


Evonik Industries formally acquired the entire RESOMER® business of Boehringer Ingelheim Pharma GmbH & Co. KG on March 1, 2011. This acquisition involved transferring the entire product portfolio comprising standard and customer-specific polymers for medical applications and pharmaceutical ...


Evonik and Boehringer Ingelheim have signed an agreement on the sale of the Resomer business to Evonik


On 22 December, 2010, Evonik Industries and Boehringer Ingelheim Pharma GmbH & Co. KG signed an agreement on the sale of the Resomer® business to Evonik. The completion of the transaction is subject to various conditions and closing is expected early March 2011. Under the agreement, the entire ...


Price increases for functional polymers for pharmaceutical applications


The Pharma Polymers business line, part of Evonik Röhm GmbH, a subsidiary of Evonik Industries AG, will implement price increases for its methyl methacrylate-based polymers for pharmaceutical applications by up to 12% for their global EUDRAGIT® business, effective January 1, 2011. The company’s ...


Enzymicals AG Acquires Proprietary Rights on Pig Liver Esterases (PLE) from Evonik AG


The Enzymicals AG gained proprietary rights for the well-known recombinant pig liver esterases (PLE) from Evonik AG in Hanau. The intellectual property (IP) covers a range of PLE isoenzymes for hydrolysis of several compounds such as esters of secondary and tertiary alcohols, lactones and ...


Evonik’s new China plant helps fortify production for pharmaceutical industry


Evonik Industries is broadening its commitment in China: The company has started up a production plant for active pharmaceutical ingredients. It will supply the Chinese market, among others, and has a capacity of 70 cubic meters that can be doubled if required. The plant, in the city of Nanning ...


Evonik strengthens its exclusive synthesis business in US

Evonik acquires Eli Lilly and Company’s U.S. Tippecanoe manufacturing site


Evonik Industries AG has agreed to acquire Indianapolis, Indiana-based Eli Lilly and Company’s Tippecanoe Laboratories manufacturing facility in Lafayette, Indiana. The site, which employs about 700, manufactures active pharmaceutical ingredients (API) and precursor materials for the ...


“Area of Competence Days” at Evonik Point to Perspectives in Biotechnology

Possibilities and opportunities are far from exhausted


White biotechnology is becoming a major driver of growth and innovation in the chemical industry of the 21st century. This was the assessment recently made by one of Evonik Industries’ largest professional conferences on white biotechnology in Marl. The event, Bio Business Perspectives, brought ...


Page 4 From 4
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE